Tag: Cancer: Prostate
Prostate-Specific Antigen Levels Posttreatment May Not Predict Overall Survival
Biochemical recurrence does not meet the criteria to be a reliable surrogate endpoint for overall survival
Common Cancer Screenings May Not Extend Life Longevity
Meta-analysis only shows a 110-day survival benefit for colorectal cancer screening with sigmoidoscopy
Prostate MRI Has Independent Screening Value
In a recent study, 16 percent of men who responded to screening invite had positive screening MRI
FDA Approves Akeega for BRCA-Positive Metastatic Prostate Cancer
Akeega plus prednisone significantly improves radiographic progression-free survival in patients with castration-resistant prostate cancer
Care at High-Volume Radiation Treatment Centers Tied to Higher Survival
Findings seen among men with very high-risk prostate cancer
Survival Similar for Black, White Prostate Cancer Patients in Clinical Trial Setting
Median PFS, OS similar for Black and White patients receiving first- or second-generation androgen receptor pathway inhibitors
PSMA-PET Improves Prediction of Biochemical Recurrence in Prostate Cancer
Risk assessment for biochemical recurrence improved with addition of PSMA PET N1/M1 status to presurgical Cancer of the Prostate Risk Assessment score
Toxicity Reduced With MRI-Guided Radiotherapy for Prostate Cancer
Odds ratios for acute grade 2 or higher genitourinary and gastrointestinal toxicities reduced for MRg-A-SBRT versus CT-SBRT
For Prostate Cancer Info Videos, Patients Prefer Hearing From a Physician
And, racial concordance between patient and physician important for trust among Black adults
Indigenous Men Less Likely to Receive PSA Testing
Indigenous men with prostate cancer are also more likely to have higher-risk disease characteristics
